니코틴대체요법 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2025-2034년)

Growth Factors of nicotine replacement therapy (NRT) Market

The global nicotine replacement therapy (NRT) market is expanding steadily, driven by the rising prevalence of tobacco use, growing awareness about its health risks, and increasing adoption of cessation therapies. NRT involves substituting tobacco products with controlled doses of nicotine in various forms, including gums, patches, lozenges, inhalers, sprays, and others. These therapies help reduce withdrawal symptoms and improve the likelihood of successful quit attempts, thereby playing a critical role in tobacco cessation programs globally.

Market Size and Forecast

According to Fortune Business Insights, the global NRT market was valued at USD 3.07 billion in 2025. The market is projected to grow to USD 3.21 billion in 2026 and is expected to reach USD 4.72 billion by 2034, reflecting a CAGR of 4.9% during 2026-2034. North America dominated the market in 2025 with a 46.72% share, driven by high adoption rates and government initiatives promoting smoking cessation.

Market Drivers

A major growth factor is the rising prevalence of tobacco use worldwide. As per WHO 2023 data, approximately 1.3 billion people globally use tobacco, contributing to cardiovascular diseases, respiratory disorders, and cancer. The awareness of tobacco's harmful effects, coupled with supportive government initiatives, is driving the adoption of NRT products.

Government programs, such as India's inclusion of NRT in the National List of Essential Medicines (NLEM) in 2022, are increasing accessibility and encouraging insurance coverage, further boosting adoption. In developed regions, initiatives like free NRT provision by Ireland's Health Service Executive (HSE) have also accelerated market growth.

Market Trends

A key trend is the shift toward over-the-counter (OTC) NRT products. Easy availability of OTC gums, lozenges, and patches in retail stores, pharmacies, and online channels has increased accessibility. For instance, Next-generation brand Sesh+ launched its NRT gum across major retailers in Canada in January 2023, supporting market expansion. Rising costs and discontinuation of prescription-based smoking cessation products have also encouraged consumers to prefer OTC NRT solutions.

Restraining Factors

Despite growth, the market faces challenges such as side effects associated with NRT products. Nicotine patches can cause skin irritation, headaches, and sleep disturbances, while gums may lead to stomach discomfort, nausea, or vomiting. Additionally, the availability of alternative products, such as e-cigarettes and vaping devices, has reduced the preference for NRT in some populations. For example, in England, 27% of adult smokers used e-cigarettes to quit, whereas only 18% used NRT products in 2022.

Market Segmentation

• By Type: The gums segment dominated the market in 2026 with 56.67% share, owing to rapid absorption and fast withdrawal relief. The patches, lozenges, and inhalers segments are also witnessing growth due to new product launches and regulatory approvals.
• By Distribution Channel: Hospital and retail pharmacies accounted for 43.5% in 2026, driven by in-store promotions and OTC availability. The online channel is expected to grow fastest, offering discounts, convenience, and accessibility for consumers.

Regional Insights

• North America: Market value reached USD 1.5 billion in 2026, with the U.S. accounting for USD 1.34 billion, driven by government initiatives and adoption of FDA-approved cessation medications.
• Europe: The UK and Germany markets are projected at USD 0.2 billion and USD 0.25 billion in 2026, respectively, with growth supported by free NRT programs and rising smoking populations.
• Asia Pacific: The Japan, China, and India markets are projected at USD 0.06B, 0.07B, and 0.03B in 2026, respectively, due to government campaigns and growing awareness of tobacco risks.
• Latin America & Middle East/Africa: These regions are expected to grow steadily due to increasing smoking prevalence and adoption of NRT products for cessation.

Competitive Landscape

The global NRT market is semi-consolidated, with key players including Johnson & Johnson Services, Inc., Haleon Group, Perrigo Company plc, Pfizer, Cipla, Dr. Reddy's Laboratories, ITC Limited, and Pierre Fabre Group. Companies focus on strategic initiatives such as mergers, acquisitions, product launches, and partnerships to expand market presence. Notable developments include FDA approval of nicotine-coated mint lozenges by Perrigo in May 2023, and Johnson & Johnson's formation of Kenvue in August 2023 to drive targeted growth strategies.

Conclusion

In conclusion, the global nicotine replacement therapy market is expected to grow from USD 3.07 billion in 2025 to USD 4.72 billion by 2034, supported by rising tobacco prevalence, growing health awareness, and increased adoption of OTC and accessible NRT products. Although side effects and alternative products like e-cigarettes may restrain growth in some regions, ongoing government initiatives, innovative product launches, and strategic efforts by major players are expected to sustain market expansion and improve smoking cessation outcomes worldwide.

Growth Rate CAGR of 4.9% from 2026-2034

Segmentation By Type

• Gums
• Patches
• Lozenges
• Inhalers
• Others

By Distribution Channel

• Hospitals & Retail Pharmacies
• Retail Stores
• Online Channels

By Region

• North America (By Type, Distribution Channel, and Country)
  • U.S. (By Type)
  • Canada (By Type)
• Europe (By Type, Distribution Channel, and Country/Sub-region)
  • U.K. (By Type)
  • Germany (By Type)
  • France (By Type)
  • Spain (By Type)
  • Italy (By Type)
  • Scandinavia (By Type)
  • Rest of Europe (By Type)
• Asia Pacific (By Type, Distribution Channel, and Country/Sub-region)
  • Japan (By Type)
  • China (By Type)
  • India (By Type)
  • Australia (By Type)
  • Southeast Asia (By Type)
  • Rest of the Asia Pacific (By Type)
• Latin America (By Type, Distribution Channel, and Country/Sub-region)
  • Brazil (By Type)
  • Mexico (By Type)
  • Rest of Latin America (By Type)
• Middle East & Africa (By Type, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa (By Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Smokers - by Countries/Sub-region, 2025/2025
• 4.2. New Product Launches
• 4.3. Key Industry Developments (Mergers, Acquisitions, and Partnerships)
• 4.4. Impact of COVID-19 on the Market

5. Global Nicotine Replacement Therapy (NRT) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Gums
  • 5.1.2. Patches
  • 5.1.3. Lozenges
  • 5.1.4. Inhalers
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital & Retail Pharmacies
  • 5.2.2. Retail Stores
  • 5.2.3. Online Channels
• 5.3. Market Analysis, Insights and Forecast - By Geography
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Nicotine Replacement Therapy (NRT) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Gums
  • 6.1.2. Patches
  • 6.1.3. Lozenges
  • 6.1.4. Inhalers
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital & Retail Pharmacies
  • 6.2.2. Retail Stores
  • 6.2.3. Online Channels
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Nicotine Replacement Therapy (NRT) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Gums
  • 7.1.2. Patches
  • 7.1.3. Lozenges
  • 7.1.4. Inhalers
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital & Retail Pharmacies
  • 7.2.2. Retail Stores
  • 7.2.3. Online Channels
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Nicotine Replacement Therapy (NRT) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Gums
  • 8.1.2. Patches
  • 8.1.3. Lozenges
  • 8.1.4. Inhalers
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital & Retail Pharmacies
  • 8.2.2. Retail Stores
  • 8.2.3. Online Channels
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Nicotine Replacement Therapy (NRT) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Gums
  • 9.1.2. Patches
  • 9.1.3. Lozenges
  • 9.1.4. Inhalers
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital & Retail Pharmacies
  • 9.2.2. Retail Stores
  • 9.2.3. Online Channels
• 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Nicotine Replacement Therapy (NRT) Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Gums
  • 10.1.2. Patches
  • 10.1.3. Lozenges
  • 10.1.4. Inhalers
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.2.1. Hospital & Retail Pharmacies
  • 10.2.2. Retail Stores
  • 10.2.3. Online Channels
• 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Haleon Group of Companies
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Johnson & Johnson Services, Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Perrigo Company plc
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Pierre Fabre group
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Pfizer, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Cipla, Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Dr. Reddy's Laboratories Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. ITC Limited
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)